Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.47 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.47 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | G6PD | P11413 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.45 |
| ▸ | AKT2 | P31751 | 6/20 | 0.44 |
| ▸ | PRKACA | P17612 | 3/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | PRKACG | P22612 | 2/20 | 0.43 |
| ▸ | PRKACB | P22694 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30862619 | 0.75 | PI4KA (0.55) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| SCHEMBL4943558 | 0.75 | PDPK1 (0.54) | LMNAMAP3K5PDPK1CDK2CYP1A2 | |
| SCHEMBL7035594 | 0.74 | PI4KA (0.50) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| SCHEMBL1989291 | 0.71 | NISCH (0.40) | CYP1A2 | |
| SCHEMBL3778190 | 0.70 | AKT2 (0.48) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| SCHEMBL7027245 | 0.70 | AKT2 (0.47) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| SCHEMBL19288719 | 0.70 | AKT2 (0.54) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| SCHEMBL2938675 | 0.69 | AKT2 (0.70) | AKT2PRKACAPRKACGPRKACBCDC7 | |
| SCHEMBL3492637 | 0.69 | AKT2 (0.50) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| SCHEMBL655396 | 0.68 | PDPK1 (0.47) | PI4KAPI4K2BPI4K2API4KBLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1895841-A2 | METHODS FOR SELECTIVE N-9 GLYCOSYLATION OF PURINES | Brigham Young University (US) | 2008-03-12 | — | — | EP | claimed |
| WO-2006138396-A2 | METHODS FOR SELECTIVE N-9 GLYCOSYLATION OF PURINES | BRIGHAM YOUNG UNIVERSITY, TRANSFER TECHNOLOGY OFFICE (US) | 2006-12-28 | — | — | WO | claimed |
| US-20150376219-A1 | Selective Preparations of Purine Nucleosides and Nucleotides: Reagents and Methods | ZHONG MINGHONG (US) | 2015-12-31 | — | — | US | disclosed |
| EP-1895841-A2 | METHODS FOR SELECTIVE N-9 GLYCOSYLATION OF PURINES | Brigham Young University (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006138396-A2 | METHODS FOR SELECTIVE N-9 GLYCOSYLATION OF PURINES | BRIGHAM YOUNG UNIVERSITY, TRANSFER TECHNOLOGY OFFICE (US) | 2006-12-28 | — | — | WO | disclosed |
| WO-2002018404-A9 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | HOFFMANN LA ROCHE (CH) | 2003-10-02 | — | — | WO | disclosed |
| EP-1315736-A2 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-04 | — | — | EP | disclosed |
| WO-2002018404-A2 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-07 | — | — | WO | disclosed |
| US-5849769-A | N-arylalkyl-N-heteroarylurea and guandine compounds and methods of treating HIV infection | MEDIVIR AB (SE) | 1998-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376219-A1 | Selective Preparations of Purine Nucleosides and Nucleotides: Reagents and Methods | PNP, ATIC, NT5C3B | PI4KA 718/4885PI4K2B 753/4885PI4K2A 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.